Giles J, Alama P, Gamiz P, et al. - Ovarian response as well as reproductive outcomes were compared between oocyte donors undergoing pituitary suppression with medroxyprogesterone acetate (MPA) vs those undergoing conventional treatment with a gonadotropin-releasing hormone (GnRH) antagonist. Researchers conducted a prospective, randomized, controlled trial of cycles evaluating ovarian response in terms of the number of oocytes. A total of 318 donors were randomly divided into 2 groups in a 1:1 ratio. Researchers assigned the oocytes retrieved to 364 recipients. Treatment of 161 donors included a daily dose of 10 mg of MPA administered orally from the beginning of ovarian stimulation (OS), and of 156 donors included a GnRH antagonist (initiated once the leading follicle reached a diameter of 13 mm). Outcomes revealed similar oocyte retrieval rates, endocrine profiles, viable embryo numbers, and pregnancy outcomes between the groups. Hence, use of MPA can be recommended for OS in oocyte donation as it permits a more patient-friendly approach.